Abstract
Tumor necrosis factor (TNF) is a central pro-inflammatory cytokine that regulates the expression of numerous signaling pathways implicated in the progression of the immunological reaction. Unraveling the importance of TNF on the pathogenesis of inflammatory bowel disease (IBD) promoted anti-TNF antibodies as novel therapeutic agents. Initially, the main hypothesis behind the clinical application of anti-TNF antagonists in the clinic was that they exert their effects solely through neutralization of TNF. Anti-TNF antibodies induce and maintain clinical remission in patients with minimal side-effects. However, the cellular and molecular mechanisms of actions of the anti-TNF antibodies remain unknown. Various mechanisms of action have been proposed such as activation of transmembrane TNF mediated reverse signaling, induction of apoptosis, pro-inflammatory cytokine down-regulation, complement dependent cytotoxicity, antibodydependent cell-mediated cytotoxicity, and finally activation of regulatory immune cells via interactions with the Fc receptors. The observed discrepancies in the clinical efficacies as well as the differences in the structure of the various TNF antagonists nourish the investigation for additional modes of function.
Keywords: Antibody-dependent cell-mediated cytotoxicity, complement dependent cytotoxicity, Crohn’s disease, inflammatory bowel disease, macrophages, reverse signaling, tumor necrosis factor, ulcerative colitis.
Current Drug Targets
Title:Anti-TNF Antibodies in Inflammatory Bowel Disease: Do We Finally Know How it Works?
Volume: 14 Issue: 12
Author(s): Angelos Oikonomopoulos, Welmoed K. van Deen and Daniel W. Hommes
Affiliation:
Keywords: Antibody-dependent cell-mediated cytotoxicity, complement dependent cytotoxicity, Crohn’s disease, inflammatory bowel disease, macrophages, reverse signaling, tumor necrosis factor, ulcerative colitis.
Abstract: Tumor necrosis factor (TNF) is a central pro-inflammatory cytokine that regulates the expression of numerous signaling pathways implicated in the progression of the immunological reaction. Unraveling the importance of TNF on the pathogenesis of inflammatory bowel disease (IBD) promoted anti-TNF antibodies as novel therapeutic agents. Initially, the main hypothesis behind the clinical application of anti-TNF antagonists in the clinic was that they exert their effects solely through neutralization of TNF. Anti-TNF antibodies induce and maintain clinical remission in patients with minimal side-effects. However, the cellular and molecular mechanisms of actions of the anti-TNF antibodies remain unknown. Various mechanisms of action have been proposed such as activation of transmembrane TNF mediated reverse signaling, induction of apoptosis, pro-inflammatory cytokine down-regulation, complement dependent cytotoxicity, antibodydependent cell-mediated cytotoxicity, and finally activation of regulatory immune cells via interactions with the Fc receptors. The observed discrepancies in the clinical efficacies as well as the differences in the structure of the various TNF antagonists nourish the investigation for additional modes of function.
Export Options
About this article
Cite this article as:
Oikonomopoulos Angelos, van Deen K. Welmoed and Hommes W. Daniel, Anti-TNF Antibodies in Inflammatory Bowel Disease: Do We Finally Know How it Works?, Current Drug Targets 2013; 14 (12) . https://dx.doi.org/10.2174/13894501113149990164
DOI https://dx.doi.org/10.2174/13894501113149990164 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nimodipine Reappraised: An Old Drug With a Future
Current Neuropharmacology Immunosuppressive Therapies in Solid Organ Transplantation
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Development and Validation of a Simple LC-UV Method to Assay Doxazosin in Polymeric Nanocapsules and Tablets
Current Pharmaceutical Analysis Atrial Fibrillation with a Focus on Oral Antiarrhythmic Therapy
Current Drug Therapy Model Systems for Pulmonary Infectious Diseases: Paradigms of Anthrax and Tuberculosis
Current Topics in Medicinal Chemistry Pulmonary Embolism Response Team (PERT) - A New Paradigm for the Treatment of Pulmonary Embolism
Current Pharmaceutical Design Discovery of an Unexplored Protein Structural Scaffold of Serine Protease from Big Blue Octopus (Octopus cyanea): A New Prospective Lead Molecule
Current Drug Discovery Technologies Endothelin-1 Actions on Vascular Smooth Muscle Cell Functions As a Target for the Prevention of Atherosclerosis
Current Vascular Pharmacology Nitroxides as Cancer Imaging Agents
Anti-Cancer Agents in Medicinal Chemistry The Role of Levomilnacipran in the Management of Major Depressive Disorder: A Comprehensive Review
Current Neuropharmacology Diabetic Nephropathy: Focus on Current and Future Therapeutic Strategies
Current Drug Metabolism Delayed Cerebral Ischemia after Subarachnoid Hemorrhage: From Vascular Spasm to Cortical Spreading Depolarizations
Current Neurovascular Research Pediatric Heart Failure in the Developing World
Reviews on Recent Clinical Trials Avocado (Persea americana) Seed as a Source of Bioactive Phytochemicals
Current Pharmaceutical Design Biology and Therapeutic Applications of Peroxisome Proliferator- Activated Receptors
Current Topics in Medicinal Chemistry Unraveling Monoamine Receptors Involved in the Action of Typical and Atypical Antipsychotics on Glutamatergic and Serotonergic Transmission in Prefrontal Cortex
Current Pharmaceutical Design Pyrazoline: A Promising Scaffold for the Inhibition of Monoamine Oxidase
Central Nervous System Agents in Medicinal Chemistry Synthesis, Anticonvulsant and Binding Interaction Study of Novel Piperamides with Bovine Serum Albumin by Fluorescence Spectroscopy
Central Nervous System Agents in Medicinal Chemistry Pulmonary Hypertension: Clinical Presentation, Diagnosis, Treatment,and Dana Point World Symposium Highlights
Current Respiratory Medicine Reviews Current Biological Therapies for Inflammatory Bowel Disease
Current Pharmaceutical Design